This trial is evaluating whether Bazedoxifene and Conjugated Estrogens will improve 1 primary outcome, 1 secondary outcome, and 2 other outcomes in patients with Breast Cancer. Measurement will happen over the course of baseline to 6 months.
This trial requires 120 total participants across 2 different treatment groups
This trial involves 2 different treatments. Bazedoxifene And Conjugated Estrogens is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
Breast cancer is a malignant disease of the breast tissue in which a cancer's cells grow in large clusters and invade the surrounding breast or neighboring tissues. It accounts for 5% of all newly diagnosed cancer cases. Older women and women who have never had a child have about 5% higher risk. Breast cancer has a 5-year survival rate of 88%, and mortality rate is about 14%.
The most common treatment is mastectomy, followed by chemotherapy plus tamoxifen (TAM). Other treatments include breast-conserving therapy, radiation, chemotherapy, chemotherapy plus tamoxifen and trastuzumab. There is a great deal of evidence supporting the best use of adjuvant therapy, that is, chemotherapy and/or radiotherapy to manage and treat [breast cancer](https://www.withpower.com/clinical-trials/breast-cancer). The American College of Surgeons Practice Patterns Committee, American College of Surgeons National Quality Forum, and the American Cancer Society recommend that adjuvant treatment be considered in node-negative breast cancer and for all women with at least one node negative breast in the sentinel lymph node.
Breast cancer is more common in some geographic locations than other geographic locations. Also, women who developed breast cancer were more likely than their female peers not to consume milk or have had mammae, which may explain why the women seem to be less affected by breast cancer. Breast cancer can have several causes, including genetics and external factors.\n
Most women are not aware of their signs of cancer. However, most women are aware of breast cancer symptoms such as nipple soreness. It is important to know how signs of cancer can influence a woman's behavior. The signs can be used to assess breast cancer risks and may help the patient and their physician make a decision about the likelihood of relapse.
About 4 million women will be diagnosed with breast cancer during their lifetime, and 3 million will be diagnosed after age 70. The lifetime risk of getting breast cancer is 13% for white women and 3% for African American women.
Although many patients with sporadic breast cancer and even some in the BRCA families do not have symptoms at the time, many develop symptoms in later life. With modern treatment, breast cancer cannot be cured.
This article describes two very different compounds which, in vitro or in clinical studies, act on the same cellular targets in a synergistic way: bazedoxifene and conjugated estrogens. Because both compounds modulate the target proteins differently, this should be taken into account by the medical staff prescribing the agents and the patients involved before a joint action is carried out.
A small number of patients may develop [metastatic [breast cancer](https://www.withpower.com/clinical-trials/breast-cancer)](https://www.withpower.com/clinical-trials/metastatic-breast-cancer) from a first screen-detection of small breast cancer lesions, but the majority develop distant metastase from clinically and biologically early stage disease. The small risk of cancer in the ipsilateral breast on mammography or ultrasonography must be weighed against the potentially destructive nature of overt breast mass or the need for diagnostic evaluation and treatment.
There was limited evidence of improvement in outcomes for those who used alternative cancer treatments. The evidence for alternative treatments for breast cancer remains inconclusive. Further investigation should be directed at further defining the efficacy of alternative treatments, which may entail implementing clinical trials.
This is the oldest cohort described in the world to be tested for BRCA1 or BRCA2 germline mutations. In our cohort of family members who reported no history of breast or [ovarian cancer](https://www.withpower.com/clinical-trials/ovarian-cancer), the mean age at diagnosis was 62 years (range: 49-68 years). An average of 24% of individuals had multiple family members with cancer; family history did not correlate with the number of affected relatives. This cohort did not differ from the general population in terms of age at diagnosis, sex, race, ethnicity, mammographic density, or family history of cancer. These data support an age of diagnosis at a later age in women with breast cancer when compared with age of diagnosis in the general population.
Breast cancer has the power to destroy a woman's life. And it's a life in which she doesn't have a future. It seems that the more a woman knows beforehand, the less is her life destroyed.
After 4 weeks of therapy, side effects of estrogens were similar to those detected with placebo. However, with conjugated estrogens bazedoxifene and ethinylestradiol a statistically significant reduction of uterine bleeding was observed. No cardiovascular events was found.